Evidence map›Paper›PMID 37445977›Full record

ArticleInternational journal of molecular sciences2023

A Novel Strategy for Screening Tumor-Specific Variable Domain of Heavy-Chain Antibodies.

Abdur Rafique, Genki Hichiwa, Muhammad Feisal Jatnika, Yuji Ito

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abdur RafiqueGraduate School of Science and Engineering, University of Kagoshima, Kagoshima 890-0065, Japan.
Genki HichiwaGraduate School of Medical Sciences, Tottori University, Tottori 680-8550, Japan.ORCID 0000-0002-3892-7456
Muhammad Feisal JatnikaGraduate School of Science and Engineering, University of Kagoshima, Kagoshima 890-0065, Japan.
Yuji ItoGraduate School of Science and Engineering, University of Kagoshima, Kagoshima 890-0065, Japan.ORCID 0000-0002-5239-5070
International University of Kagoshima · JPTottori University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The properties of the variable domain of heavy-chain (VHH) antibodies are particularly relevant in cancer therapy. To isolate tumor cell-specific VHH antibodies, VHH phage libraries were constructed from multiple tumor cells. After enriching the libraries against particular tumor cell lines, a next-generation sequencer was used to screen the pooled phages of each library for potential antibody candidates. Based on high amplification folds, 50 sequences from each library were used to construct phylogenetic trees. Several clusters with identical CDR3 were observed. Groups X, Y, and Z were assigned as common sequences among the different trees. These identical groups over the trees were considered to be cross-reactive antibodies. To obtain monoclonal antibodies, we assembled 200 sequences (top 50 sequences from each library) and rebuilt a combined molecular phylogenetic tree. Groups were categorized as A-G. For each group, we constructed a phagemid and determined its binding specificity with tumor cells. The phage-binding results were consistent with the phylogenetic tree-generated groups, which indicated particular tumor-specific clusters; identical groups showed cross-reactivity. The strategy used in the current study is effective for screening and isolating monoclonal antibodies. Specific antibodies can be identified, even when the target markers of cancer cells are unknown.

Indexed as

Antibodies, MonoclonalImmunoglobulin Heavy ChainsCell Line, TumorGene LibraryPeptide LibraryPhylogenyAntibodies, MonoclonalImmunoglobulin Heavy ChainsPeptide Librarycancercell lineflow cytometrynext-generation sequencingphylogenetic treetherapyVHH

Identifiers

PMID37445977
PMCPMC10341490
OpenAlexW4382727010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.